Physician profile
William Thomas Trost
NPI 1528025822
$1,836.06
in general payments reported to CMS, 2019-2025
20 companies · $438 in 2025
The $438 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $363 · 2020: $303 · 2021: $181 · 2022: $188 · 2023: $79.13 · 2024: $284 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $800.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $375.43 | 2019-2025 | Invega Sustenna, Spravato, Invega |
| Alkermes, INC. | $229.09 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $212.60 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $191.97 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $160.47 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $109.86 | 2019-2021 | |
| Axsome Therapeutics, INC. | $109.39 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $77.47 | 2021-2024 | Caplyta |
| Lundbeck LLC | $75.60 | 2022-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $71.52 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $39.13 | 2021-2022 | |
| Indivior INC. | $31.37 | 2019-2022 | |
| Allergan, INC. | $23.48 | 2019-2020 | |
| Biogen, INC. | $22.74 | 2025 | Zurzuvae |
| Corium, LLC | $21.99 | 2023 | Azstarys |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $19.45 | 2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $18.36 | 2025 | Mounjaro, Zepbound |
| Dexcom, INC. | $17.33 | 2025 | Dexcom G6 Transmitter |
| Noven Therapeutics, LLC | $16.80 | 2021 | |
| Mdd US Operations, LLC | $12.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Trost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.